InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
MWN-AI** Summary
InnoCare Pharma (HKEX: 9969; SSE: 688428), a biopharmaceutical company based in Beijing, has announced the approval of a Phase II/III clinical trial for its novel TYK2 inhibitor, soficitinib (ICP-332), aimed at treating chronic spontaneous urticaria (CSU) in China. This approval comes from the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA). Soficitinib is a selective inhibitor targeting the TYK2 enzyme, which is integral to the JAK-STAT signaling pathway implicated in various inflammatory and autoimmune disorders, particularly those affecting T-cells.
Chronic spontaneous urticaria is marked by recurrent itchy hives and can significantly impact patients' quality of life. It often persists for years, with a global estimate of 50 million individuals suffering from the condition. The necessity for effective long-term management of CSU is underscored by its disruptive symptoms, leading to a significant demand for innovative treatments. The global market for CSU therapies is anticipated to reach $3 billion by 2029.
Dr. Jasmine Cui, InnoCare’s Co-founder and CEO, emphasized the importance of this development in addressing the unmet medical needs in dermatology, particularly for autoimmune conditions. She reaffirmed InnoCare's commitment to accelerating the clinical development of soficitinib, aiming to offer timely solutions to patients in need.
InnoCare Pharma is dedicated to pioneering treatments for cancer and autoimmune diseases, with ongoing projects to ensure the availability of groundbreaking drugs within the rapidly expanding healthcare sectors in China and globally. With its operational branches in key regions, the company is well-positioned to make significant strides in biopharmaceutical innovation.
MWN-AI** Analysis
InnoCare Pharma (HKEX: 9969; SSE: 688428) has recently achieved a critical milestone with the approval of its Phase II/III clinical trial for soficitinib, a novel TYK2 inhibitor aimed at treating chronic spontaneous urticaria (CSU). This development positions InnoCare favorably within the competitive biopharmaceutical landscape, particularly as the global CSU treatment market is projected to grow to $3 billion by 2029.
Investors should view this approval as a bullish indicator, reflecting InnoCare’s robust pipeline and ongoing commitment to addressing significant unmet medical needs. The company’s strategic focus on autoimmune disorders aligns with a growing demand for innovative therapies in the expanding dermatology sector. Given the high prevalence of CSU—approximately 50 million patients worldwide—soficitinib could command a substantial share of the market, especially considering its targeted approach to mitigating the debilitating symptoms associated with the condition.
Furthermore, InnoCare's capabilities in drug development, coupled with its broad portfolio, which includes ten major autoimmune diseases, enhance its market position. The potential for soficitinib to serve as a first-in-class therapy could lead to competitive advantages, including premium pricing and market share.
However, investors should remain cognizant of the risks associated with clinical trials, including potential delays and regulatory hurdles. Monitoring the trial's progress, as well as any announcements regarding efficacy and safety, will be crucial for assessing the investment's timelines and value creation.
In conclusion, InnoCare’s approval for soficitinib represents a pivotal step that could lead to significant growth. Given the company’s strategic positioning and the expected expansion of the CSU treatment market, it may be prudent for investors to consider building or maintaining positions in InnoCare as clinical outcomes progress and market dynamics evolve.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BEIJING, Dec. 17, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct a Phase II/III clinical trial of novel TYK2 inhibitor soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU).
Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The current indications under development are strategically positioned within the vast dermatology market, including atopic dermatitis, vitiligo, prurigo nodularis, CSU, and more. TYK2 plays a key role in the JAK-STAT signaling pathway and is critical in the pathogenesis of inflammatory diseases.
Soficitinib blocks signaling pathways such as lL-4, IL-13, IL-31, and other cytokines that drive mast cell activation and inflammation, reducing itch and wheals in CSU.
CSU is characterized by recurrent wheals and itch, with a disease course typically lasting two to five years, and in some patients, even exceeding five years. China has a large population of CSU patients, a condition that is prone to recurrent episodes. The intense nighttime itching severely disrupts daily life. Long-term, systematic, and standardized treatment is therefore essential for disease control.
There are approximately 50 million CSU patients worldwide1, and the global CSU treatment market is expected to reach $3 billion in 20292.
Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “InnoCare's pipeline under development covers ten major autoimmune diseases, with our TYK2 inhibitors deeply positioned in the field of dermatology. We are accelerating the clinical development of soficitinib to address huge unmet medical needs. We hope this innovative drug will benefit more autoimmune disease patients as early as possible.”
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
1 DOI: 10.1007/s12325-025-03172-0
2 The Business Research Company
Contact
| Media Chunhua Lu 86-10-66609879 chunhua.lu@innocarepharma.com | Investors 86-10-66609999 ir@innocarepharma.com |
FAQ**
How does InnoCare Pharma (INCPF) plan to leverage the recent IND approval for soficitinib in chronic spontaneous urticaria (CSU) to enhance its market presence in the dermatology sector?
What are the expected timelines for the Phase II/III clinical trial of soficitinib, and how might this impact InnoCare Pharma (INCPF)'s long-term growth strategy?
Given the projected $3 billion global CSU treatment market by 2029, what competitive advantages does InnoCare Pharma (INCPF) believe soficitinib has over existing therapies?
How is InnoCare Pharma (INCPF) addressing the unmet medical needs in autoimmune disorders, and what role does soficitinib play in this broader strategy?
**MWN-AI FAQ is based on asking OpenAI questions about InnoCare Pharma (OTC: INCPF).
NASDAQ: INCPF
INCPF Trading
0.0% G/L:
$1.55 Last:
1,000 Volume:
$1.55 Open:
